• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » Intuitive Surgical inks pact, buys 3% of Cardica

Intuitive Surgical inks pact, buys 3% of Cardica

August 18, 2010 By MassDevice staff

ISRG, CRDC logos

Intuitive Surgical Inc. (NSDQ:ISRG) and Cardica Inc. (NSDQ:CRDC) agreed to integrate Cardica’s micro-cutter technology for Intuitive’s da Vinci robotic surgery system and for Intuitive to pick up a 3 percent stake in Cardica.

With revenues from one licensing and development agreement on hold, Cardica went out and inked a similar pact August 17. Cardica executives have spent more than a year looking for ways to expand use of its linear cutter staplers — endoscopic devices that form inter-locking lines of “nails” in a zipper pattern, rather than with sewn sutures — beyond its current indications for cardiac procedures. The $12 million deal also sets up additional selling features for Intuitive’s increasingly successful da Vinci surgical system, which incorporates high-vision tools with robotic mechanics designed to mirror a surgeon’s natural hand movements.

Cardica has financial as well as strategic motivations for expanding its potential customer base. In a separate announcement, the company said total net revenues during the three months ended June 30 fell 50 percent from year-ago levels, to $1 million. Product sales also declined, sliding from $1.2 million during Q2 2009, as $815,000 in development revenues from a licensing agreement with Cook Group Inc. evaporated. The companies scrapped work on a vascular closure device and suspended development of a device designed to seal holes between chambers of the heart.

Under the new agreement, Intuitive gains exclusive global rights to sell da Vinci systems fitted with Cardica microcutters for general surgery via a royalty-bearing license slated to pay Cardica about $10 million. Intuitive also purchased 1.25 million shares of Cardica stock, worth about $2.1 million at its $1.66-a-share closing price on Tuesday. The deal did not include Cardica’s vascular anastomosis applications, which are already being marketed by the company in the U.S. and Europe under its PAS-port and C-Port product lines.

The collaboration between the companies dates back to at least early 2008, when they jointly hosted a seminar on robotic surgery at the annual meeting of the Society for Thoracic Surgeons. During a conference call yesterday with analysts, Cardica CEO Bernard Hausen declined to discuss specific terms of the deal, including potential royalty payments, but said product income from the new partnership was unlikely to have a material impact on its financial results over the short term.

Hausen also acknowleged that the deal could eventually pit Cardica and Intuitive against industry heavyweights such as Covidien plc (NYSE:COV) that are also starting to market surgical stapling tools. In response to a question, he said his firm likely can match other would-be rivals on price and may have the upper hand with respect to performance.

“We believe we have a major advantage in the design features of our microcutter,” Hausen said, checking off attributes including its smaller size, flexibility and “staple-on-a-strip” platform, which allows surgeons to fire staples multiple times without removing the device from the patient.

Future partnerships between the firms, or between Cardica and other companies, on additional product lines also are possible, Hausen said, again declining to elaborate. In all, the company holds 82 U.S. patents, with the latest — an anastomosis tool capable of moving in two directions relative to the handle — assigned Aug. 3.

Second-quarter results were of another order for Intuitive, which crushed year-ago comparisons and blew through analyst expectations for the quarter, posting a $89 million profit during the three months ended June 30 on $351 million in revenues.

Filed Under: Business/Financial News, MassDevice Earnings Roundup, News Well, Surgical Tagged With: dextera, Intuitive Surgical

In case you missed it

  • CeQur is launching a discreet, convenient ‘wearable insulin pen’
  • Teva appoints former Vertex exec as new head of R&D, CMO
  • Enovis partners with Kelvi on hot and cold therapies
  • West Pharmaceutical Services debuts new needle syringe system
  • Titan Medical names Cary G. Vance as new president, CEO
  • Acutus completes first closing in left-heart access portfolio sale to Medtronic
  • FDA clears Intuitive, Siemens Healthineers imaging integration for robotic bronchoscopy
  • FDA backs COVID-19 boosters with BA.4/5 spike proteins for fall
  • How safe is health information after the overturning of Roe?
  • Smith+Nephew opens new plant in Malaysia
  • BD launches combination COVID-19, flu, RSV diagnostic test
  • Zimmer Biomet creates independent nonprofit organization to reduce health disparities
  • Dexcom focuses on early diabetes diagnosis as COVID links emerge
  • Nasdaq grants Titan Medical 180-day extension to regain compliance
  • Aerin Medical reports positive 4-year results for VivAer treatment
  • Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
  • How medical device companies are responding to abortion bans

RSS From Medical Design & Outsourcing

  • Supply Chain EVP Greg Smith sees fewer suppliers in Medtronic’s future
    All eyes are on Medtronic’s global operations and supply chain leader as he works to modernize its operations and scrutinize suppliers. EVP of Global Operations and Supply Chain Greg Smith anticipates fewer suppliers in Medtronic’s future, he said in an interview this week. Smith spoke with DeviceTalks Editorial Director Tom Salemi in his first published… […]
  • CeQur is launching a discreet, convenient ‘wearable insulin pen’
    CeQur designed its Simplicity device to make insulin delivery as seamless as possible for people with diabetes. When it comes to managing diabetes, CeQur wants to make insulin therapy as convenient as possible. For those who prefer to manage their own insulin delivery, the Simplicity device might just do exactly that. Simplicity, a wearable, disposable… […]
  • Meddux opens new facility in Colorado
    Engineering, design, development and manufacturing company Meddux announced that it opened a new facility in Boulder, Colorado. The new, 22,000-square-foot facility doubles the overall square footage from its previous location in Colorado. According to a news release, it helps the company to quadruple its product development area and double its manufacturing footprint. Meddux’s new facility… […]
  • Reducing the Overall Cost of Validation
    By PTI Engineered Plastics Reliable medical devices and equipment are essential for researchers and doctors to accurately diagnose and treat a wide range of diseases. That is why there is such stringent oversight from the FDA to ensure these products meet the necessary requirements and specifications. To ensure compliance with regulators, manufacturers follow installation qualification… […]
  • BBS Automation has a deal to buy medtech supplier Kahle Automation
    BBS Automation said it plans to purchase high-speed automation supplier Kahle Automation to expand its medtech and life sciences business. Kahle will operate as Kahle – a BBS Company, according to a news release from Munich, Germany-based BBS and Lombardy, Italy-based Kahle. The deal is subject to regulatory approval. Terms were not disclosed. Kahle’s co-owners —… […]
  • How safe is health information after the overturning of Roe?
    The U.S. Department of Health and Human Services today issued guidance meant to better protect women’s health information as state abortion bans kick in after the U.S. Supreme Court’s overturning of Roe v. Wade. Despite the HHS actions, women may still wonder whether their health information is entirely safe going forward — a potential challenge… […]
  • Dexcom focuses on early diabetes diagnosis as COVID links emerge
    New evidence is showing that COVID-19 may increase a person’s risk of diabetes, but it could be years until we know for sure. In the meantime, Dexcom (Nasdaq:DXCM) is getting ready, VP of Global Clinical Initiatives Tomas Walker said. Walker recently spoke with Medical Design & Outsourcing to discuss the San Diego-based diabetes device developer’s… […]
  • Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
    Blackrock Neurotech and the University of Pittsburgh’s Rehab Neural Engineering Labs (Pitt RNEL) are working together on the first portable brain-computer interface (BCI) to allow patients to participate in research trials from home. A Blackrock representative said it’s the final step as the company prepares to launch its first commercial product early next year. Salt… […]
  • How medical device companies are responding to abortion bans
    Days after the U.S. Supreme Court’s decision to overturn Roe v. Wade’s protection of abortion rights, medical device companies are among those reassuring workers about healthcare access. Corporate communications to employees and the public at large come as trigger laws in nearly half of the states outlaw abortion immediately. Some medtech companies are not using… […]
  • Philips updates on testing results for recalled ventilators
    Royal Philips (NYSE:PHG) says only a small portion of returned respiratory devices displayed the sound abatement foam degradation that sparked a massive recall. Repeated ozone cleaning may have made the problem worse. Those were some of the major takeaways from an update Philips provided today on a comprehensive test and research program it implemented after its… […]
  • ResMed names Lucile Blaise as new Sleep & Respiratory Care leader
    Lucile Blaise will be the new president of ResMed’s Sleep & Respiratory Care business starting July 1, ResMed (NYSE: RMD) said today. She replaces Jim Hollingshead, who became president and CEO of Insulet (Nasdaq:PODD) on June 1. ResMed President and COO Rob Douglas is serving as interim president of the Sleep & Respiratory Care during… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS